1. Home
  2. POOL vs KRYS Comparison

POOL vs KRYS Comparison

Compare POOL & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pool Corporation

POOL

Pool Corporation

HOLD

Current Price

$205.38

Market Cap

9.5B

ML Signal

HOLD

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$251.13

Market Cap

7.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POOL
KRYS
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5B
7.8B
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
POOL
KRYS
Price
$205.38
$251.13
Analyst Decision
Buy
Strong Buy
Analyst Count
10
10
Target Price
$292.29
$297.60
AVG Volume (30 Days)
691.4K
195.7K
Earning Date
04-23-2026
05-05-2026
Dividend Yield
2.50%
N/A
EPS Growth
N/A
128.00
EPS
10.85
6.84
Revenue
$5,289,396,000.00
$389,130,000.00
Revenue This Year
$4.51
$40.88
Revenue Next Year
$3.98
$35.16
P/E Ratio
$18.49
$36.80
Revenue Growth
N/A
33.94
52 Week Low
$197.68
$123.03
52 Week High
$345.00
$298.30

Technical Indicators

Market Signals
Indicator
POOL
KRYS
Relative Strength Index (RSI) 36.28 43.56
Support Level N/A $248.73
Resistance Level $227.80 $293.60
Average True Range (ATR) 5.69 9.06
MACD 0.38 -0.42
Stochastic Oscillator 28.67 30.85

Price Performance

Historical Comparison
POOL
KRYS

About POOL Pool Corporation

Pool Corp distributes swimming pool supplies and related products. Its products include non-discretionary pool-maintenance products, like chemicals and replacement parts, as well as pool equipment, like packaged pools (kits to build swimming pools), cleaners, filters, heaters, pumps, and lights. Customers include pool builders and remodelers, independent retail stores, and pool repair and service companies.

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Share on Social Networks: